Company Name: |
SPIRO PHARMA
|
Tel: |
|
Email: |
eric_feng1954@126.com |
Products Intro: |
Product Name:ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- CAS:1049722-30-6 Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
|
Company Name: |
Beijing Jin Ming Biotechnology Co., Ltd.
|
Tel: |
010-60605840 18892239720 |
Email: |
psaitong@jm-bio.com |
Products Intro: |
Product Name:Targapremir-210 CAS:1049722-30-6 Purity:98% Package:5mg;10mg;25mg;50mg;100mg
|
|
| ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Basic information |
| ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Chemical Properties |
storage temp. | Store at -20°C | solubility | DMSO: 250 mg/mL (421.81 mM) |
| ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Usage And Synthesis |
Biological Activity | Targapremir-210 (TGP-210) is a potent and selective miR-210 inhibitor. It can inhibits pre-miR-210 processing with high affinity (Kd~200 nM). | in vitro | Targapremir-210 decreases mature miR-210 levels in MDA-MB-231 cells cultured under hypoxic conditions, with an IC 50 of~200 nM. It (200 nM) induces apoptosis in MDA-MB-231 cells is selective for the hypoxic environment. Targapremir-210 induces apoptosis in cells under hypoxic conditions and does not induce apoptosis in MDA-MB-231 cells cultured in normoxia. | in vivo | Targapremir-210 (100 μL of 200 nM; single ip injection) impedes MDA-MB-231 triple negative breast cancer (TNBC) cells proliferation in vivo. It is able to reach the tumor and sustain for the entire 21-day period, and decreases tumor burden in a TNBC mouse model. | target | IC50: 200 nM (miR-210, in MDA-MB-231 cells). | storage | Store at -20°C |
| ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Preparation Products And Raw materials |
|